Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study

Autor: Monique K. van der Kooij, Arjen Joosse, Karijn P. M. Suijkerbuijk, Maureen J. B. Aarts, Franchette W. P. J. van den Berkmortel, Christian U. Blank, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Djura Piersma, Rozemarijn S. van Rijn, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Hans M. Westgeest, Michel W. J. M. Wouters, Olaf M. Dekkers, Ellen Kapiteijn
Přispěvatelé: Interne Geneeskunde, MUMC+: MA Medische Oncologie (9), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Guided Treatment in Optimal Selected Cancer Patients (GUTS), Medical Oncology, Radiology & Nuclear Medicine
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: British Journal of Cancer, 128, 5, pp. 707-710
British Journal of Cancer. SPRINGERNATURE
British Journal of Cancer
British Journal of Cancer, 128(5), 707-710. Nature Publishing Group
British Journal of Cancer. Nature Publishing Group
British Journal of Cancer, 128, 707-710
ISSN: 0007-0920
DOI: 10.1038/s41416-022-02088-8
Popis: Treatment with targeted therapy and immune checkpoint inhibitors has significantly improved survival of patients with advanced melanoma. Unfortunately, a large proportion of patients are either primary non-responders or will eventually develop secondary resistance. In 2017, Nosrati and colleagues published a prediction scale in the British Journal of Cancer, which included five clinical parameters that were associated with lower response to anti-PD-1 treatment; female sex (1 point), age 1]. This study used a derivation cohort of 228 patients treated in California, and a validation cohort of 87 patients treated in Switzerland. The primary outcome measure was best tumour response to treatment evaluated using computed tomography at 12 and 16 weeks after the first administration of anti-PD-1 monotherapy, and every 12 weeks thereafter. The aim of this correspondence is to validate the prediction scale, published by Nosrati and colleagues.
Databáze: OpenAIRE
Externí odkaz: